Literature DB >> 10935025

Conditional control of gene expression in the mammary gland.

P A Furth1.   

Abstract

Identifying gene function during mammary gland development and function remains a technical challenge. For example, if a gene deletion is lethal during early embryogenesis, there is no opportunity to study its effects on the development or function of the gland. Similarly, if a dominant gain of gene function alters early mammary gland development, then its specific role during lactation cannot be assessed. Conditional gene expression systems can be used to circumvent these problems. Gene deletions or dominant gain experiments can be performed in an organ or cell type specific manner at specific timepoints using inducible gene expression systems. This review focuses on tetracycline responsive transactivation and Cre-lox systems. Other tetracycline regulatable (tet system) or hormone inducible systems and the Flp recombinase system are discussed as alternative approaches. Each system is described. The advantages and disadvantages of each for studying gene function in the mammary gland are discussed. Finally, the role of mammary gland transplantation in these genetic studies is examined.

Entities:  

Mesh:

Year:  1997        PMID: 10935025     DOI: 10.1023/a:1026399329934

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  55 in total

1.  Stoichiometry of the Cre recombinase bound to the lox recombining site.

Authors:  A Mack; B Sauer; K Abremski; R Hoess
Journal:  Nucleic Acids Res       Date:  1992-09-11       Impact factor: 16.971

2.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

3.  Temporal control of the Cre recombinase in transgenic mice by a tetracycline responsive promoter.

Authors:  L St-Onge; P A Furth; P Gruss
Journal:  Nucleic Acids Res       Date:  1996-10-01       Impact factor: 16.971

4.  Ecdysone-inducible gene expression in mammalian cells and transgenic mice.

Authors:  D No; T P Yao; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

5.  Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase.

Authors:  Y Kanegae; G Lee; Y Sato; M Tanaka; M Nakai; T Sakaki; S Sugano; I Saito
Journal:  Nucleic Acids Res       Date:  1995-10-11       Impact factor: 16.971

6.  Targeted oncogene activation by site-specific recombination in transgenic mice.

Authors:  M Lakso; B Sauer; B Mosinger; E J Lee; R W Manning; S H Yu; K L Mulder; H Westphal
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

7.  Ligand-inducible and liver-specific target gene expression in transgenic mice.

Authors:  Y Wang; F J DeMayo; S Y Tsai; B W O'Malley
Journal:  Nat Biotechnol       Date:  1997-03       Impact factor: 54.908

8.  Specificity of action of a herpes virus VP16/tetracycline-dependent trans-activator in mammalian cell cultures.

Authors:  A Magalini; F Ferrari; G Savoldi; R Ingrassia; A Albertini; G Pollio; C Patrone; A Maggi; D Di Lorenzo
Journal:  DNA Cell Biol       Date:  1995-08       Impact factor: 3.311

9.  Ligand-activated site-specific recombination in mice.

Authors:  R Feil; J Brocard; B Mascrez; M LeMeur; D Metzger; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

10.  Tetracycline-reversible silencing of eukaryotic promoters.

Authors:  U Deuschle; W K Meyer; H J Thiesen
Journal:  Mol Cell Biol       Date:  1995-04       Impact factor: 4.272

View more
  12 in total

Review 1.  Developing a mammary gland is a stat affair.

Authors:  L Hennighausen; G W Robinson; K U Wagner; X Liu
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-10       Impact factor: 2.673

Review 2.  Mammary gland immunity and mastitis susceptibility.

Authors:  Lorraine M Sordillo; Katie L Streicher
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

Review 3.  Genetically engineered ERα-positive breast cancer mouse models.

Authors:  Sarah A Dabydeen; Priscilla A Furth
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

Review 4.  Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.

Authors:  Priscilla A Furth; M Carla Cabrera; Edgar S Díaz-Cruz; Sarah Millman; Rebecca E Nakles
Journal:  Ann N Y Acad Sci       Date:  2011-07       Impact factor: 5.691

Review 5.  The role of prolactin in mammary carcinoma.

Authors:  Charles V Clevenger; Priscilla A Furth; Susan E Hankinson; Linda A Schuler
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

Review 6.  Analysis of lactation defects in transgenic mice.

Authors:  Carol A Palmer; Margaret C Neville; Steven M Anderson; James L McManaman
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-10       Impact factor: 2.673

Review 7.  BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer.

Authors:  Edgar S Diaz-Cruz; Marina C Cabrera; Rebecca Nakles; Beth H Rutstein; Priscilla A Furth
Journal:  Breast Dis       Date:  2010

8.  Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma.

Authors:  Maddalena T Tilli; M Silvina Frech; Mary E Steed; Kathleen S Hruska; Michael D Johnson; Jodi A Flaws; Priscilla A Furth
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

9.  A mouse mammary epithelial cell model to identify molecular mechanisms regulating breast cancer progression.

Authors:  Vassiliki Karantza-Wadsworth; Eileen White
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

Review 10.  Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer?

Authors:  Anneke C Blackburn; D Joseph Jerry
Journal:  Breast Cancer Res       Date:  2002-04-18       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.